Scilex Holding Company(SCLX)

Description: Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc., is an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Scilex is uncompromising in its focus to become the global pain management leader committed to social, environmental, economic, and ethical principles to responsibly develop pharmaceutical products to maximize quality of life. Results from the Phase III Pivotal Trial C.L.E.A.R Program for SEMDEXA™, its novel, non-opioid product for the treatment of lumbosacral radicular pain (sciatica), were announced in March 2022. Scilex targets indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with moderate to severe pain.

---

Keywords: Pharmaceutical Products Pain Organ Systems Pain Management Chronic Pain Opioids Acute Pain Palliative Care Nociception Acute And Chronic Pain Majority Owned Subsidiary

---

Home Page: www.scilexholding.com

SCLX Technical Analysis

960 San Antonio Road
Palo Alto, CA 94303
United States
Phone: 650 516 4310

---

Officers

Exchange: NASDAQ

Country: US : United States of America

Currency: US Dollar ($)